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ABSTRACT  
Objective: The World Health Organization estimates that about 8 to 10 million new Tuberculosis (TB) cases occur annually worldwide and its 
incidence is currently increasing. There are two million deaths from TB each year. The global threat of tuberculosis demands the search for 
alternative antimycobacterial drugs. 
Methods: The liquid media for fermentation was prepared in TSB alone, LB alone and TSB + LB (1:1) supplemented with six different carbon 
sources (fructose, maltose, dextrose, mannitol, sucrose and lactose) and after fermentation crude extract was extracted using ethyl acetate. The 
minimum inhibitory concentration (MIC) of extracts was determined using the broth dilution method on middle brook 7H11 against M. tuberculosis 
H
The aim of the present study was to determine the antimycobacterial activity of nine crude extracts from a 
Bacillus sp. N strain associated with entomopathogenic nematode Rhabditis (Oscheius) sp.  
37
Results: Out of nine extract tested only two recorded activity and significant activity was recorded by TSB+LB+lactose, followed by 
TSB+LB+fructose. These two extracts were nontoxic to the normal cell line.  
Rv. The cytotoxicity of the extracts was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay against 
VERO cell line.  
Conclusion: Purification of these extract will get pure compounds with antimycobacterial activity in future. 
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INTRODUCTION 
Tuberculosis (TB) is a chronic infectious disease caused mainly by 
Mycobacterium tuberculosis [1, 2]. The World Health Organization 
(WHO) estimated that almost 9 million new cases and 1.4 million TB 
deaths (990,000 among HIV-negative people and 430 000 HIV-
associated TB deaths), occurred in 2011 [3]. Ninety-five percent of 
TB cases are produced in underdeveloped countries, 80% of them 
corresponding to the 15 to 29-year-old group, generating strong 
socioeconomic problems [3]. Furthermore, the lack of treatment 
adherence has given rise to antibiotic-resistant M. tuberculosis 
strains in many parts of the world. 
Tuberculosis is mostly asymptomatic and is aggravated when 
impairment of immunity arises due to conditions like malnutrition, 
diabetes, malignancy, and AIDS. Weakening of the immune system 
by HIV increases vulnerability to other infections and diseases 
caused by M. avium complex has also increased [4]. This 
phenomenal increase is due to their weak immune system 
compromised by stress, immunosuppressive drugs, substance abuse, 
or HIV/AID [5]. HIV infection is the greatest single medical risk 
factor because cell-mediated immunity, which is impaired by HIV, is 
essential for defense against mycobacterial infection; other 
immunosuppressive illnesses (e. g., diabetes) or therapies (e. g., 
corticosteroids) are risks but less so than HIV. The problem of multi-
drug resistant strains of mycobacteria has made the search for more 
efficacious, safer, cheaper, and more accessible drugs a priority. The 
search for new and better anti-mycobacterial drugs has informed 
our present study of medicinal plants with folk reputations as 
effective alternative therapies for mycobacteria infections. 
A major problem for the control of TB is the requirement of drug 
regimens for six to nine months. These lengthy regimens lead to 
non-compliance with therapy, relapse and development of drug 
resistance. In order to shorten the duration of therapy, novel drugs 
that are active against Mycobacterium, which act through 
mechanisms different from those employed by the existing frontline 
and secondary anti-TB drugs are urgently needed. The emergence of 
antibiotic resistant mycobacterial strains underscores the need for 
novel effective drugs against resistant mycobacteria as first-line 
antituberculosis medications. According to World Health 
Organization (WHO), between 1980 and 2005, 90 million cases of TB 
worldwide were reported [6]. 
Bacteria of the genera Xenorhabdus and Photorhabdus are known to 
be symbiotically associated with the soil dwelling entomopathogenic 
nematodes (EPN) of the family Steinernematidae and 
Heterorhabditidae, respectively [7]. The antimicrobial nature of 
metabolites produced by Xenorhabdus spp. and Photorhabdus spp. is 
known, and several compounds with biological activity have been 
isolated and identified [8]. In the course of studies on EPN, a new 
EPN belonging to the genus Rhabditisand subgenus Oscheius was 
isolated from sweet potato weevil grubs collected from Central 
Tuber Crops Research Institute (CTCRI) farm, Thiruvananthapuram, 
Kerala, India. In the present study, we investigated the 
antimycobacterial activity of the crude extract from the above 
bacterium against M. tuberculosisH37
MATERIALS AND METHODS 
Rv. 
All chemicals used for extraction and purification were of AR grade 
(Merck, Mumbai, India). Microbiological media were purchased from 
the Hi-media Laboratories Limited, Mumbai, India. The carbon 
source used is fructose was purchased from the SRL Laboratories 
Limited, Mumbai. 
Fermentation media preparation 
Bacterial isolate was inoculated into the liquid medium. The liquid 
media was prepared in TSB alone, LB alone and TSB + LB (1:1) 
supplemented with 1% of six different carbon sources (fructose, 
maltose, dextrose, mannitol, sucrose and lactose). Thus a total of 9 
different combinations where used in the study. The media pH was 
adjusted to 7.0 before autoclaving using NaOH or HCl solution. 
Hundred mL aliquots of each media containing one each of different 
carbon and nitrogen sources were dispensed separately in 250 mL 
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Erlenmeyer flasks and this was inoculated with a loop full of the 
bacterial culture. The flasks were incubated in a controlled 
environment, gyrorotatory shaker (150 rpm at 30 ºC in darkness for 
24 – 48 hours. When the optical density of the culture at 600 nm was 
approx. 1.7 (AU), the bacterial cultures were transferred into 400 
mL sterile medium and incubated in a gyrorotatory shaker (150 
rpm) at 30 ºC in darkness for 96 hours. The culture media were then 
centrifuged (10,000 rpm, 20 min, 4 º
Preparation of crude organic extract  
C) followed by filtration through 
a 0.45µM filter, to obtain cell free culture filtrate. 
The cell free culture filtrate (500 mL) was neutralized with 1 N HCl 
and extracted with an equal volume (500 mL) of ethyl acetate thrice. 
The ethyl acetate extracts were combined, dried over anhydrous 
sodium sulphate, and concentrated using a rotary flash evaporator 
at 30 º
Antimycobacterial activity of crude extracts 
C to obtain the crude extract. 
Mycobacterium Tuberculosis strains 
M. tuberculosis H37Rv was used as the sensitive strain used for the 
study. H37
Growth media 
Rv are internationally used as standard M. tuberculosis 
strain for sensitivity testing. 
Middle brook 7H10 agar supplemented with oleic acid-albumin-
catalase (OADC) was used for reviving and culturing the 
mycobacterium for sensitivity testing. The medium was from Becton 
Dickinson Microbiology Systems of Becton Dickinson Company 
(Difco TM), 7 Loveton Circle, Sparks, Maryland, USA; Lot No. 
8175150. The OADC, Lot 8136781, also from Becton Dickinson 
Company. No adjustments for pH were made. 
Preparation of inoculum for drug sensitivity testing 
Preserved strains were revived on middle brook 7H10 agar, prior to 
anti tubercular susceptibility testing. Colonies were scraped from 
freshly growing colonies (three weeks old) on middle brook 7H10 
plates and introduced into 10 ml of saline. Bacterial suspensions 
with 0.5 McFarland standard turbidity equivalents to 105
Preparation of test compounds for susceptibility testing 
 CFU/ml 
were prepared by dilution with saline. The tubes were vigorously 
vortexed for 30 seconds in a glass bottle containing glass beads and 
the particles were allowed to settle. 
A stock solution, 2 mg/ml for crude extract, was prepared by 
suspending each test extract in absolute ethanol. Rifampicin was 
prepared as a 1 mg/ml stock suspension in absolute ethanol. The 
stock solutions were stored in aluminum foil-wrapped bottles at 4°C. 
As a high percentage of ethanol could be bactericidal, the amount of 
ethanol added to the growth medium was kept as low as possible in 
order to minimize the potential effect on growth of M. tuberculosis. A 
preliminary experiment was carried out to determine the maximum 
percentage of ethanol which could be included in the growth 
medium without growth inhibition of M. tuberculosis and it was 
found to be 0.8% (v/v) (data not shown). The final concentration of 
ethanol present in the growth medium was standardized at 0.4% 
(vol/vol) in this study. Before the test, each stock solution was 
serially diluted (threefold) in middle brook 7H9 broth to yield final 
concentrations of 2 to 2000 µg/ml for crude extracts. For rifampicin, 
the final concentrations were 0.02 to 1 µg/ml. Ethanol at 0.4% 
(vol/vol) was added to the growth medium to serve as a negative 
control. 
Determination of the Minimum Inhibitory Concentration (MIC) 
The micro plate method was performed to determine the MICs of 
test extract [9]. Briefly, a 100 µl volume of Middlebrook 7H9 broth 
was dispensed in each well of a 96-well cell culture plate. Serial 
dilutions of the test extracts (2000-2 µg/ml) were used to determine 
the minimum inhibitory concentration, using middle brook 7H9 as 
the medium. Perimeter wells of the plate were filled with sterile 
water to avoid dehydration of the medium during incubation. A 
standard bacterial suspension equivalent in turbidity to that of a no. 
1 McFarland standard was prepared and diluted 1:20 in 7H9 broth; 
a 100 ml inoculum was used to inoculate each well of the plate. A 
growth control containing no test extract and a sterile control 
without inoculum were also included. Plates were sealed and 
incubated at 37°C for 4 week. The lowest concentration of the test 
extract in the test tubes with no visible or detectable bacterial 
growth was considered to represent the MIC. 
Disc diffusion susceptibility test 
Bacterial suspension was prepared from 14-days M. tuberculosis 
cultures grown on Middlebrook 7H11 agar slant, supplemented with 
10% oleic acid, bovine serum albumin (fraction V), dextrose, and 
catalase (OADC; Remel, Lenexa, KS, USA) and 0.05% Tween 80. The 
turbidity of the suspension was adjusted to a McFarland no. 3 (9×108
Determination of cytotoxicity of crude in VERO cells 
 
CFU/ml) in sterile normal saline. The bacterium was spread on 
Middlebrook 7H11 agar plates, then discs with MIC concentration of 
test compounds were placed on the plates. All plates were incubated 
at 37°C for 4-8 weeks before measuring the diameter of the zone of 
inhibition of extract[10]. 
The MTT assay was used to determine the cytotoxicity (IC50) in 
VERO cells at concentrations of 50 to 500 µg/ml of crude extract. 
After 72 h of exposure, viability was assessed on the basis of cellular 
conversion of MTT into a formazan product using the Promega Cell 
Titer 96 Non-radioactive Cell Proliferation Assay [11]. Briefly, 20 μl 
of MTT solution (5 mg/mL PBS) were added to each well. Samples 
were incubated for further 4 h at 37°C in 5% CO2 and humidified air 
atmosphere. Then, 100 μl of 10% SDS were added to extract the 
insoluble product formazan, resulting from the conversion of the 
MTT dye by viable cells. The number of viable cells in each well was 
proportional to the intensity of the absorbance of light, which was 
then read in an ELISA plate reader at 570 nm. Absorbance (A) at 570 
nm was measured 24 h later. To get cell survival (%), A of a sample 
with cells grown in the presence of various concentrations of the 
investigated extracts was divided with control optical density (the A 
of control cells grown only in nutrient medium), and multiplied by 
100. It was implied that A of the blank was always subtracted from A 
of the corresponding sample with target cells. IC50
Results 
 concentration 
was defined as the concentration of an agent inhibiting cell survival 
by 50%, compared with a vehicle-treated control. 
MIC  
The data of antimycobacterial activity of crude extract are shown in 
Table 1. Two out of the nine crude extract tested were found to 
inhibit the growth of M. tuberculosis strains during incubation at 
37°C for up to 42 days. The most effective compound was TSB+LB+ 
lactose, with a MIC of 125 µg/ml, followed by TSB+LB+ fructose(250 
µg/ml) (Table 1). It appeared that effective MIC also represents the 
effective bactericidal concentration of the bacteria tested. The 
activity of the crude extract was compared with that of rifampicin 
and the data is shown in Table 1. 
Disc diffusion 
The data of disc diffusion assay of test extract was also shown in 
Table 1. Best activity was recorded by TSB+LB+ lactose (35 mm). 
 
Table 1: Antimycobacterial activity of crude extract 
Media MIC Diameter of zone of inhibition 
(mm) 
TSB - - 
LB - - 
TSB+LB - - 
TSB+LB+ fructose 250 23±0.77 
TSB+LB+ maltose - - 
TSB+LB+ glucose - - 
TSB+LB+mannitol - - 
TSB+LB+ sucrose - - 
TSB+LB+ lactose 125 35±0.52 
Rifampicin 28 0.5 
- Not active 
Sasidharan et al. 




TSB+LB+ fructose and lactose alone was subjected to cytotoxicity 
activity. The two extracts were nontoxic to VERO cell up to 500 
µg/ml. This clearly indicated that these extracts were safe for 




Fig. 1: Cytotoxic activity of crude extract against normal cell line 
 
DISCUSSION 
Natural products are a proven template for the development of new 
scaffolds of drugs [12] and they have received considerable 
attention as potential anti-TB agents20. The emergence of 
pathogenic microbes with increased resistance to established 
antibiotics provides a major incentive for the discovery of new 
antimicrobial agents [13]. Due to emergence of resistance to 
antibiotics amongst microorganisms especially M. tuberculosis, 
investigations for novel anti TB agents have always been one of the 
major preoccupations of medical society. Additional 
chemotherapeutic agents were recognized in the early 20th
Rifampicin is typically used to treat 
 century. 
The discovery of antibiotics and other antimicrobial chemicals, and 
studies on their mode of action, have allowed us to control a great 
variety of TB. In the present study the crude extract from 
TSB+LB+lactose recorded significant antimycobacterial activity and 
purification of this extract in future may leads to pure compound 
which elevated antimycobacterial activity. 
Mycobacterium infections, 
including tuberculosis and Hansen's disease and the most 
serious adverse effect is related to rifampicin hepatotoxicity. In our 
present study significant activity and low cytotoxicity makes the 
crude extract as an ideal antimycobacterial drug after purification in 
the near future. This study is the first report of anti-mycobacterial 
activity of the crude extracts isolated from an entomopathogenic 
nematode against M. tuberculosis. 
CONCLUSION 
The results of this study have revealed that crude extract has 
reasonable antimycobacterial activity, and is relatively safe for use 
in as far as lethality is concerned. This therefore validates its use in 
the treatment of tuberculosis by traditional practitioners. However 
more studies on the purification of crude extract are needed for 
getting pure antimycobacterial active compounds. 
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